ICAAC

2018 – Andras Farkas, Sofie Dhaese, Jason A. Roberts, Jeffrey Lipman, Veronique Stove, Alain Vestraete, Jan De Waele3; Population Pharmacokinetics of Continuous Infusion Meropenem in Critically Ill Patients: A Comparison of Eight Approaches

2018 – Andras Farkas, Phillip Villasurda, Jason A. Roberts; Population Pharmacokinetics and Pharmacodynamics of Intraperitoneal Gentamicin During Continuous Ambulatory Peritoneal Dialysis

2017 – A. Farkas; Villasurda P; LaFortune A; K. Sarosky; G. Mckinley ; Pharmacodynamic evaluation of daily dalbavancin dosing regimens for endocarditis therapy caused by Staphylococcus aureus with elevated vancomycin MIC: semi-mechanistic modeling of rabbit infection data to investigate predicted efficacy of human dosing strategies

2015 – A. Farkas; N. Gujadhur; B. Yasin; T. Felton; J. Roberts ; Model-based Prediction of Piperacillin Concentrations in Critically Ill Patients: A Comparison of Nine Approaches Against Clinical Data

2015 – A. Farkas; O. Frey; J. Robert; A. C. Rohr ; Evaluation of the Utility of a Bayesian Feedback Method at Predicting Future Linezolid Concentrations in Critically Ill Patients

2015 – A. C. Roehr; O. R. Frey; S. Helbig; A. Farkas; J. A. Roberts; A. Brinkmann ; Continuous Infusions of Linezolid, a 4-Year Practical Experience with Critically Ill Patients

2014 – Farkas A.; Saju S.; Galdun P.; Kuriyilel J.; Villasurda P.; Roberts J.; Comparative evaluation of the performance of a population equation and two Bayesian methods to predict future Vancomycin concentrations

2014 - Farkas A.; Villasurda P.; Feldfogel H.; Afroz S.; Evaluation Of The Safety And Efficacy Of Low Versus High Vancomycin Trough Levels For The Treatment Of Conditions Caused By Methicillin-Resistant Staphylococcus Aureus

2013 – Farkas A, Daroczi G, Saunders-Hao P; Individually Designed Optimum Dosing Strategies (ID-ODS), a multi-model based online application to individualize antibiotic dosing in critically ill patients

2011 – Farkas A, Hoffman C; Population probability of target attainment of telavancin at different levels of renal function against Methicillin Resistant Staphylococcus Aureus in US medical centers